From PsychonautWiki
(Redirected from 2c-p)
Jump to navigation Jump to search
Summary sheet: 2C-P
Chemical Nomenclature
Common names 2C-P
Substitutive name 2,5-Dimethoxy-4-propylphenethylamine
Systematic name 2-(2,5-Dimethoxy-4-propylphenyl)ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 1 mg
Light 2 - 6 mg
Common 6 - 10 mg
Strong 10 - 16 mg
Heavy 16 mg +
Total 10 - 20 hours
Onset 1 - 3 hours
Come up 2 - 4 hours
Peak 4 - 8 hours
Offset 3 - 6 hours
After effects 8 - 48 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


2,5-Dimethoxy-4-propylphenethylamine (also known as 2C-P) is a lesser-known novel psychedelic substance of the phenethylamine class. 2C-P is a relatively obscure member of the 2C-x family of psychedelic phenethylamines, which are closely related to the classical psychedelic mescaline. It is known as one of the most potent, dose-sensitive, and long-lasting of the series. Although the precise mechanism is not known, it is thought to produce its psychoactive effects by activating serotonin receptors in parts of the brain.

2C-P was first synthesized and tested for human activity by the American chemist Alexander Shulgin, who documented his findings in the 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").[1] The reports found in the 2C-P PiHKAL entry remark on its depth and long onset and duration of action, with the commentary section describing 16 mg as a clear overdose with "physical consequences." The commentary also notes the small window separating an adequate dose from an excessive dose, suggesting it is relatively easy to overdose on.

Subjective effects include open and closed-eye visuals, time distortion, conceptual thinking, euphoria, and ego loss. User reports tend to characterize the effects of 2C-P in terms of its unusually long duration, powerful, sometimes overwhelming visuals, and intense "body load" consisting of nausea, muscle tension, and general bodily discomfort. Some reports suggest it may be easier to experience agitation and delirium on 2C-P than other 2C's, perhaps owing to the ease in which it can be mis-dosed. As a result, it is considered to have an unfavorable safety profile among psychedelics.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-P. Due its powerful effects and unusually long duration, 2C-P may be overly intense and difficult to use safely for those who are not highly experienced with hallucinogens. It is strongly advised to use harm reduction practices if using this substance. These include avoiding "eye-balling" (i.e. measuring the dose with the naked eye instead of a reliable milligram scale) and non-oral routes of administration. Volumetric liquid dosing is commonly recommended when dealing with substances of this potency.


2C-P or 2,5-dimethoxy-4-propylphenethylamine is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-P contains methoxy functional groups CH3O- attached to carbons R2 and R5 and a propyl chain attached to carbon R4 of the phenyl ring. 2C-P belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.[2]


Further information: Serotonergic psychedelic

2C-P's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how it results in the psychedelic experience continues to remain elusive.

Subjective effects

2C-P's head space and visuals have been described as possessing more similarities to alkylated 2C's like 2C-E than halogenated members like 2C-B or 2C-I.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.

Physical effects

Visual effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

The toxicity and long-term health effects of recreational 2C-P use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-P is a research chemical with very little history of human usage.

Anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.


The LD50 of 2C-P has not been established. However, it is believed that 2C-P is likely to have a smaller therapeutic window compared to other 2C's, meaning a lethal dose may be achieved more easily. 2C-P is known to be highly dose-sensitive: a difference of 2 or 5 milligrams may radically change the nature of the experience along with its safety profile. Users who wish to take high doses of this compound are advised to titrate upward slowly, use reliable milligram scales to measure doses, and avoid non-oral routes of administration such as insufflation or injection.

In 2017, a 25-year old British female died following the ingestion of a large dose of 2C-P at a music festival.[3] No source reported clear evidence that 2C-P by itself led to the immediate death of the female.

Dependence and abuse potential

As a serotonergic psychedelic, 2C-P is considered to have a low potential for abuse and dependence.

Tolerance to the effects of 2C-P are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-P produces cross-tolerance with all psychedelics, meaning that after the consumption of 2C-P all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Cannabis - Cannabis has an unexpectedly strong and somewhat unpredictable synergy with the effects of psychedelics. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
  • Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops, and paranoia. This interaction may result in an elevated risk of mania and psychosis.[citation needed]
  • Lithium - Lithium is often prescribed as a treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.[citation needed]
  • Tramadol - Tramadol lowers the seizure threshold[4] and psychedelics may act as triggers for seizures in susceptible individuals.[citation needed]

Legal status

2C-P is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: 2C-P is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Canada: 2C-P would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[5]
  • China: As of October 2015, 2C-P is a controlled substance in China.[6]
  • Denmark: 2C-P is on the list of Schedule B controlled substances.[7]
  • Germany: 2C-P is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014.[8][9] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[10]
  • Latvia: 2C-P is a Schedule I controlled substance.[11]
  • Switzerland: 2C-P is a controlled substance specifically named under Verzeichnis E.[12]
  • Turkey: 2C-P is a classed as drug and is illegal to possess, produce, supply, or import.[13]
  • United Kingdom: 2C-P is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[14]
  • United States: 2C-P is a Schedule I controlled substance.[15] This means 2C-P is illegal to manufacture, buy, possess, process, or distribute without a license from the Drug Enforcement Administration (DEA).

See also

External links



  1. https://erowid.org/library/books_online/pihkal/pihkal.shtml | PiHKAL
  2. http://isomerdesign.com/PiHKAL/read.php?id=36
  3. Morris, S. (2019, February 13). Bestival death may be world's first 2C-P fatality, court hears. Retrieved from https://www.theguardian.com/uk-news/2019/feb/13/bestival-death-may-be-worlds-first-2-cp-fatality-court-hears
  4. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
  5. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  6. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  7. https://www.retsinformation.dk/Forms/R0710.aspx?id=137169
  8. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019. 
  9. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  10. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  11. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  12. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  13. https://resmigazete.gov.tr/eskiler/2011/02/20110213-4.htm
  14. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made
  15. http://www.justice.gov/ola/views-letters/112/093011-ltr-re-hr1254-synthetic-drug-control-act-2011.pdf